University of Michigan collaborations:
National and international collaborations:
Deakin University, Australia
Johns Hopkins University *
Penn State Hershey College of Medicine
Stanford School of Medicine
University of Balamand and Institute for Development, Research, Advocacy, and Applied Care (IDRAAC), Lebanon
Weizmann Institute of Science, Israel
Weill Cornell Medical College
Institutions of Higher Education that requested samples or data from the Heinz C. Prechter Bipolar Research Program:
Institute for Systems Biology
University of Texas Health Science Center
Michigan State University
University of Chicago
University of Illinois, Urbana Champaign
University of Wisconsin
Institutions of Higher Education that are using our PRIORI app:
Butler Hospital, which is the major affiliated teaching hospital for psychiatry and behavioral health at The Warren Alpert Medical School of Brown University. Read the press release about the $2.9 million grant the research group received to support the study of suicide risk assessment.
We are engaged in several national and international research projects in bipolar disorder.
PGBD study: Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder
The Pharmacogenomics of Bipolar Disorder study (PGBD) is a research study of patients with bipolar disorder and the role of genes in their response to medications. The study focuses on two of the most commonly used mood stabilizing medications, lithium and valproate (Depakote®). The goal is to identify the genes that influence whether a patient will have a good response to these medications. This study began in 2010 and recently the last patient was enrolled at the Michigan site. They will be monitored for two years to determine if they are responsive to lithium or valproate.
University of California *
University of Chicago
University of Pennsylvania *
University of Iowa *
Johns Hopkins University
Case Western University
University of Michigan
Mayo Clinic *
National Network of Depression Centers (NNDC)
The NNDC’s mission is to develop and foster connections among members to use the power of our network, to advance scientific discovery, and to provide stigma free, evidence-based care to patients with depressive and bipolar illnesses. The NNDC envisions a global experience that is without stigma, where all patients with depressive and bipolar illnesses receive effective treatment, and access to improved quality of life.
The Prechter Program collaborates with many NNDC member sites; these are denoted by an asterisk (*) throughout this page.